Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study
Our study confirmed the efficacy and safety of both bimekizumab and brodalumab, up to 36 weeks of treatment. Although both drugs showed a significant improvement of the investigated scores from week 4, some differences in terms of PASI90 and PASI100 responses (higher for bimekizumab at each follow-up, with only PASI100 response significantly higher at week 4 and 16) were registered. No statistical significance was found for safety data and treatment failure.
Authors
- Matteo Megna (ORCID: https://orcid.org/0000-0003-1803-2046)
- Fabrizio Martora (ORCID: https://orcid.org/0000-0003-2523-050X)
- Luca Potestio (ORCID: https://orcid.org/0000-0001-5940-0592)
- Ginevra Torta (ORCID: https://orcid.org/0009-0007-5555-9994)
- Flavia Raia (ORCID: https://orcid.org/0009-0002-6988-9402)
- Claudio Brescia (ORCID: https://orcid.org/0009-0007-5094-5052)
- Gioacchino Lucagnano
Institutions
- Federico II University Hospital (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1007/s13555-025-01361-x
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.39